| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1119623B1 Mage-a3 peptides presented by hla class ii molecules |
| 04/01/2009 | CN101400670A Novel pyridine derivative having anti-helicobacter pylori activity |
| 04/01/2009 | CN101400377A Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
| 04/01/2009 | CN101400367A Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist |
| 04/01/2009 | CN101400346A Pharmaceutical combination composition comprising at least one PKC inhibitor and at least one JAK3 kinase inhibitor for treating autoimmune disorders |
| 04/01/2009 | CN101396562A Use of composition containing ARB in preparing medicine for treating hyperhomocysteinemia injury and related diseases thereof |
| 04/01/2009 | CN101396561A Use of composition containing ACEI in preparing medicine for treating hyperhomocysteinemia injury and related diseases thereof |
| 04/01/2009 | CN101396560A Medicine composition for treating polycystic kidney disease and use thereof |
| 04/01/2009 | CN101396559A Fat regulation |
| 04/01/2009 | CN101396558A Medicinal preparation for treating rhinitis and sinusitis |
| 04/01/2009 | CN101396370A Medicine composition for treating mouth, throat disease and preparation method thereof |
| 04/01/2009 | CN101396363A Composite antibacterial drugs composition containing abafungin |
| 04/01/2009 | CN101396338A Sustained-release injection containing methotrexate and synergist thereof |
| 04/01/2009 | CN100473662C Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
| 04/01/2009 | CN100473648C 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 03/31/2009 | US7511075 Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511023 adriamycin; chemotherapy; sustained release |
| 03/31/2009 | US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5 |
| 03/31/2009 | US7511010 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510851 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| 03/31/2009 | US7510847 Drug screening for compound having uricosuric regulating action by incubating a transformed cell expressing a recombinant protein with uric acid; and determining an uptake of uric acid; gout |
| 03/31/2009 | US7510830 Cancer treatment by combination therapy |
| 03/31/2009 | US7510711 Nucleotide sequence coding monoclonal antibody; anticancer agents; antiinflammatory agents; immunology disorders |
| 03/31/2009 | US7510702 Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone |
| 03/31/2009 | CA2307285C Agent for prophylaxis and treatment of glaucoma |
| 03/26/2009 | WO2009038663A1 Method of treating hepatitis c patients |
| 03/26/2009 | WO2009037855A1 Oral and skin compositions |
| 03/26/2009 | WO2009037592A2 Triazole-based aminoglycoside-peptide conjugates and methods of use |
| 03/26/2009 | WO2009037584A2 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| 03/26/2009 | WO2009037503A2 New combination - 012 for the treatment of respiratory diseases |
| 03/26/2009 | WO2009037449A1 Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| 03/26/2009 | WO2009036906A1 Composition with laxative/antifoam active ingredient combination for the treatment of constipation |
| 03/26/2009 | WO2009022897A3 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
| 03/26/2009 | WO2008137780A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases |
| 03/26/2009 | WO2008118879A3 Antiviral compositions comprising 2 compounds |
| 03/26/2009 | WO2008116641A3 Oleyl phosphocholine |
| 03/26/2009 | WO2008039525A3 Cadherin antagonists in combination with anticancer agents for use in cancer treatment |
| 03/26/2009 | WO2007092620A3 Stable formulations, and methods of their preparation and use |
| 03/26/2009 | WO2005094553A3 Compositions for promoting bone growth and methods thereof |
| 03/26/2009 | WO2005011604A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
| 03/26/2009 | US20090082444 Compositions for the Treatment of Blood Disorders |
| 03/26/2009 | US20090082424 Small molecule antagonists of bcl-2 family proteins |
| 03/26/2009 | US20090082406 Cancer Therapy |
| 03/26/2009 | US20090082360 Use of tyrosine kinase inhibitors for treating CNS disorders |
| 03/26/2009 | US20090082309 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 by conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV; treating Type II diabetes but not sufficient to suppress the immune system of the animal |
| 03/26/2009 | US20090082296 Mycobacterial antigens expressed during latency |
| 03/26/2009 | US20090082292 inhibiting angiogenesis; corneal graft rejection; age related macular degeneration; diabetic retinopathy; dermatological disease |
| 03/26/2009 | US20090082288 Methods and compositions for the treatment of uveitis |
| 03/26/2009 | US20090082255 by addition of surfactants providing a high long-term stability due to stress; storage stability to hydrophobic aggregation nuclei for several months under temperature stress; for the treatment of diabetes; FDA Orange book listed patent for insulin glargine recombinant |
| 03/26/2009 | US20090082223 Method and kit for the determination of cellular activation profiles |
| 03/26/2009 | US20090081792 Immune potentiating compositions of cancer cells |
| 03/26/2009 | US20090081729 Compositions and Methods Comprising a Ligand of ChemerinR |
| 03/26/2009 | US20090081705 Novel peptides and compositions which modulate apoptosis |
| 03/26/2009 | US20090081635 Modified heparinase iii and methods of sequencing therewith |
| 03/26/2009 | US20090081311 Medium chain peroxycarboxylic acid compositions |
| 03/26/2009 | US20090081309 Stabilized Oral Suspension Formulation |
| 03/26/2009 | US20090081274 Mast cell-derived renin |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081215 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081214 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081180 Antimicrobial polymer conjugates |
| 03/26/2009 | US20090081179 Method for reducing the severity of neurological disorders |
| 03/26/2009 | US20090081161 Treatment of neoplasms with viruses |
| 03/26/2009 | US20090081139 Water-based delivery systems |
| 03/26/2009 | CA2699280A1 Method of treating hepatitis c patients |
| 03/26/2009 | CA2698814A1 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 03/26/2009 | CA2695435A1 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| 03/26/2009 | CA2687689A1 Triazole-based aminoglycoside-peptide conjugates and methods of use |
| 03/25/2009 | EP2039779A1 Screening method |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039369A1 Treatment of fungal infections |
| 03/25/2009 | EP2039368A2 Methods for preventing reactivation of latent virus and controlling virus replication |
| 03/25/2009 | EP2039364A2 Means and method for enhancing a human sexual activity |
| 03/25/2009 | EP2039363A1 Agent for prevention and/or treatment of glomerulopathy |
| 03/25/2009 | EP2039359A1 Analgesic agent |
| 03/25/2009 | EP2039357A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 03/25/2009 | EP2039356A1 Sialagogue composition comprising a M3 muscarinic agonist and an alpha-2 adrenergic antagonist |
| 03/25/2009 | EP2038248A2 Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer |
| 03/25/2009 | EP2037965A2 Pharmaceutical composition with synergistic anticonvulsant effect |
| 03/25/2009 | EP2037964A2 Combination preparations comprising bifeprunox and l-dopa |
| 03/25/2009 | EP2037963A2 Soft tissue repair and regeneration using stem cell products |
| 03/25/2009 | EP2037933A2 Combinations comprising staurosprorines |
| 03/25/2009 | EP2037931A2 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/25/2009 | EP2037925A1 Combinations comprising 5ht6 modulators and cholinesterase inhibitors |
| 03/25/2009 | EP2037924A2 Bicyclic heteroaryl inhibitors of pde4 |
| 03/25/2009 | EP2037917A1 Pharmaceutical composition comprising amlodipine and losartan |
| 03/25/2009 | EP2037912A2 Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
| 03/25/2009 | EP2037910A1 Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| 03/25/2009 | EP2037893A2 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
| 03/25/2009 | EP2037890A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 03/25/2009 | EP2037881A1 Steroid-containing sustained release intraocular implants and related methods |
| 03/25/2009 | EP1664852A4 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 03/25/2009 | EP1594536B1 Adjuvanted influenza vaccine |
| 03/25/2009 | EP1578401A4 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 03/25/2009 | EP1504010B1 Vitamin-mitomycin conjugates |
| 03/25/2009 | EP1353692B1 Methods and compositions for treatment of ocular neovascularization and neural injury |